Lipogems International
Lipogems International is an Italian medical technology company that develops single-use mechanical devices for processing autologous adipose tissue used in regenerative medicine. It serves orthopedic, coloproctology, wound care, gynecology, and pain management specialists across 28 countries with FDA- and CE-cleared products.
- Company typePrivate
- Founded2010
- HeadquartersMilano, Italy
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lipogems International does
Lipogems International S.p.A. is an Italian medical technology company founded in 2010 and headquartered in Milan that develops and commercializes the Lipogems System, a single-use mechanical device for processing autologous adipose tissue. The device washes, reduces, micro-fragments, and concentrates fat tissue without enzymatic digestion, preserving the vasculo-stromal niche and tissue micro-architecture in a process classified by the FDA as 'minimal manipulation of adipose tissue.' The product family comprises 60cc, 120cc, and 240cc devices, with commercial reach across 28 countries and more than 50,000 cumulative procedures performed globally.
The company operates a B2B medical device sales model, distributing kits directly through its US subsidiary (Lipogems Americas, Inc., Norcross, GA) and through exclusive channel partners including CrossLink Lifescience in North America and Sinopharm Group in China. It serves orthopedic surgeons, colorectal surgeons, wound care specialists, gynecologists, pain management physicians, and plastic surgeons, with the core commercial focus on knee osteoarthritis supported by the ARISE I and ARISE FDA IDE clinical studies, alongside adjacent indications including Crohn's disease complex perianal fistulas (ATTIC trial) and chronic wounds. Pricing is negotiated B2B and undisclosed, and the business is supported by 140+ peer-reviewed publications and regulatory approvals including FDA 510(k), CE Mark, PMDA (Japan), and TGA (Australia).
Commercially, the company is in a clinical-evidence-driven growth phase: ARISE I completed enrollment of 173 patients across 20 US centers in April 2024, ARISE II initiated enrollment the same month, and €12.5M of funding raised in 2022 is explicitly earmarked for FDA studies and US/global expansion. Leadership combines clinical founders (Carlo Tremolada, Camillo Ricordi) with senior medical device executives (CEO Giorgio Ninzoli, formerly of Smith & Nephew and Tyco Healthcare), positioning Lipogems as a specialty regenerative medicine platform seeking to convert its clinical evidence base into US reimbursement and broader commercial scale.
Lipogems International firmographics
Firmographics- Name
- Lipogems International
- Legal name
- Lipogems International S.p.A.
- Website
- https://lipogems.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lipogems International is an Italian medical technology company that develops single-use mechanical devices for processing autologous adipose tissue used in regenerative medicine. It serves orthopedic, coloproctology, wound care, gynecology, and pain management specialists across 28 countries with FDA- and CE-cleared products.
- Ownership category
- akta.pro rank
Where Lipogems International is headquartered
LocationHeadquarters
- HQ city
- Milano
- HQ country
- Italy
- HQ region
- Europe
Offices2 records
Markets served
Lipogems International business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Medical Device Sales: Lipogems generates revenue through the sale of its medical device kits for adipose tissue processing. The single-use device system is sold to hospitals, clinics, and surgeons for use in regenerative medicine procedures across multiple specialties including orthopedics, wound care, and coloproctology.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Lipogems International product offering
Product offeringCore offering
Lipogems International develops and sells the Lipogems System, a single-use medical device that washes, reduces, micro-fragments, and concentrates autologous adipose tissue for use in regenerative medicine applications. The system is available in 60cc, 120cc, and 240cc device sizes and is sold to hospitals, surgeons, and clinics across orthopedics, wound care, colorectal surgery, gynecology, pain management, and plastic/reconstructive surgery specialties.
Product overview
Lipogems International is an Italian medical technology company that operates in regenerative medicine. The company offers the Lipogems System, a single-use medical device that washes, reduces, micro-fragments, and concentrates autologous adipose tissue for use in orthopedics (particularly knee osteoarthritis), wound healing, colorectal/coloproctology (Crohn's disease fistulas), gynecology, pain management, and plastic/aesthetic surgery. The core product portfolio consists of the Lipogems System available in three device sizes (60cc, 120cc, and 240cc), all producing Microfragmented Fat (MFat) for autologous tissue transplantation. The system is CE marked, FDA cleared, and registered across multiple international markets including the USA, Japan, Australia, and the Middle East. Over 50,000 procedures have been performed worldwide, supported by more than 140 peer-reviewed publications.
Differentiator
Problem solved
Functional benefit
Products and services
- Lipogems System
Quantifiable outcome
- Efficacy in knee osteoarthritis: 68% of patients show effectiveness at 4-year follow-up
- +2 more outcomes
Companies that use Lipogems International
Customer profileNamed customers10 records
Segments6 records
Ideal customer profiles4 records
Lipogems International technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lipogems International partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered major and core.
- Alira HealthmajorCollaboration between Lipogems USA and Alira Health for the ARISE I FDA IDE clinical study. Alira Health provided support for the clinical trial execution, helping complete enrollment of 173 patients in 14 months across 20 US centers.
- CrossLink LifesciencecoreCrossLink Lifescience is the major distributor in North America of medical technologies in orthopedics, sports medicine, and pain management sectors. Created Lipogems USA LLC subsidiary with CrossLink as minority strategic partner. Located in Atlanta, Georgia.
- Sinopharm GroupcoreStrategic partnership in China for distribution of Lipogems products. Sinopharm Group is the largest state-owned pharmaceutical group in China.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Lipogems International competitors and assessment
Company assessmentDirect peers
- InGeneron: US-based regenerative medicine company developing adipose-derived stem cell therapies using point-of-care processing devices. Direct competitor in the mechanical processing of adipose tissue for orthopedic and wound care applications.
- Terumo BCT: Cell and tissue processing technology provider offering devices for regenerative medicine and cell therapy manufacturing. Comparable to Lipogems in single-use tissue processing device business.
- Cytori Therapeutics: Pioneer in adipose-derived regenerative cell therapy with Celution system for point-of-care adipose tissue processing. Closest historical peer in the adipose-derived cell therapy device category.
- EmCyte Corporation: Developer of point-of-care PRP and cell concentrate systems for orthopedic and aesthetic applications. Direct competitor in regenerative medicine device sales to physicians and clinics.
Broad incumbents
- Smith & Nephew: Major orthopedic devices and sports medicine company with REGENETEN bioinductive implant and other orthobiologic offerings. Lipogems CEO Giorgio Ninzoli is a former President (Ortho) of Smith & Nephew.
- Zimmer Biomet: Major orthopedic and sports medicine company offering regenerative solutions including PRP and BMAC systems. Competes broadly with Lipogems in the orthopedic regenerative medicine space.
- Stryker: Large diversified orthopedic and surgical device company with orthobiologics products (including MAST, bone graft substitutes). Overlaps with Lipogems in regenerative orthopedic procedures.
- Arthrex: Global leader in orthopedic devices and orthobiologics with a broad product portfolio including PRP systems (Angel System) and cartilage restoration technologies. Competes with Lipogems in orthopedic regenerative procedures.
Emerging players
- Mesoblast: Cellular medicines company developing mesenchymal stem cell therapies for inflammatory and orthopedic conditions. Competes in the regenerative medicine space for knee OA and other orthopedic indications.
- Geistlich Pharma: Swiss regenerative medicine company with bone and tissue regeneration products (Geistlich Bio-Oss, Bio-Gide). Operates in adjacent regenerative medicine categories with similar physician customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Lipogems International social profiles
Digital presenceLipogems International compliance and trust
Trust signalCompliance6 records
Lipogems International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lipogems International leadership team
Management profileNumber of profiles
Profiles9 records
Lipogems International subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lipogems International funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lipogems International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lipogems International
What does Lipogems International do?
Lipogems International develops and sells the Lipogems System, a single-use medical device that washes, reduces, micro-fragments, and concentrates autologous adipose tissue for use in regenerative medicine applications. The system is available in 60cc, 120cc, and 240cc device sizes and is sold to hospitals, surgeons, and clinics across orthopedics, wound care, colorectal surgery, gynecology, pain management, and plastic/reconstructive surgery specialties.
Is Lipogems International a public or private company?
Lipogems International is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lipogems International founded?
Lipogems International was founded in 2010. It employs 1 to 10 people.
Where is Lipogems International based?
Lipogems International is headquartered in Milano, Italy, in the Europe region.
How does Lipogems International make money?
One revenue line is on record: medical Device Sales.
Who are Lipogems International's main competitors?
Direct peers on record are InGeneron, Terumo BCT, Cytori Therapeutics and EmCyte Corporation. Broad incumbents are Smith & Nephew, Zimmer Biomet, Stryker and Arthrex. Emerging players are Mesoblast and Geistlich Pharma.
Does Lipogems International have an API?
No public API is recorded for Lipogems International.